GlaxoSmithKline PLC is pinning the future of its HIV business on an audacious bet: upending the decades-old treatment strategy that has turned a fatal illness into a chronic condition.
The treatment of HIV, the virus that causes AIDS, has changed little since the mid-1990s, when the introduction of a new class of drug dramatically improved HIV therapy. Doctors found that combining the newer type of antiretroviral drug with two drugs from an earlier class hindered the virus from developing resistance.
The treatment of HIV, the virus that causes AIDS, has changed little since the mid-1990s, when the introduction of a new class of drug dramatically improved HIV therapy. Doctors found that combining the newer type of antiretroviral drug with two drugs from an earlier class hindered the virus from developing resistance.
